Related Experiment Video
Updated: Apr 28, 2026
10:26
Inducing Apical Periodontitis in Mice
Published on: August 6, 2019
12.3K
Periapical radiolucency not requiring endodontic therapy: an unusual case
K Vijay Venkatesh1, V Vidyashree Nandini
1Department of Conservative Dentistry and Endodontics, SRM Kattankulathur Dental College and Hospital, Potheri, Chennai, India.
Summary
Primary hyperparathyroidism, a rare disorder, can manifest unusually in the mandible. This case report emphasizes thorough radiographic examination before dental treatments like root canals.
Area of Science:
- Endocrinology and Oral Medicine
- Radiology in Dental Practice
Background:
- Primary hyperparathyroidism (PHPT) is a rare endocrine disorder characterized by excessive parathyroid hormone secretion.
- PHPT can present with extraskeletal manifestations, including rare occurrences in the jaws, often mimicking dental pathology.
- Early diagnosis is crucial for managing hypercalcemia and preventing complications.
Observation:
- A case report detailing an unusual mandibular manifestation of primary hyperparathyroidism.
- Pre- and post-treatment radiographic findings of this rare dental presentation are documented.
- The patient's initial symptoms were primarily dental, leading to consideration of endodontic therapy.
Findings:
- Radiographic analysis revealed distinct features associated with PHPT in the mandible, necessitating a differential diagnosis beyond typical dental issues.
- The case underscores the potential for jaw lesions to be the initial clinical sign of PHPT.
- Successful management involved addressing the underlying endocrine disorder, not solely the dental symptoms.
Implications:
- Highlights the importance of integrating systemic disease awareness into dental diagnostics, particularly for unexplained jaw lesions.
- Stresses the critical role of comprehensive clinical and radiographic evaluation in differentiating dental from systemic conditions.
- Informs dental practitioners about rare but significant oral manifestations of primary hyperparathyroidism, potentially altering treatment pathways.
